In summary, this study represents the first comprehensive investigation on the role of ROS-mediated DNA damage and the ATM-p53 signaling pathway involved in PLB induced cell cycle arrest, which underlines that ROS are the major weapon used by PLB to exhibit its anti-HCC effects and its potential clinical application. This evidence concerns the gene TP53 and hepatocellular carcinoma.